5 Stocks to Watch: Week of 4/21/2025

Happy Sunday. We’re hopping into this holiday with a fresh set of stocks to watch for the week ahead, including:

• Carnival Corp (NYSE: CCL) continues to cruise 
• Why Nutex Health Inc. (NUTX) surged 300% in 3 months
• The ultimate pandemic play is back: Here’s why Zoom Communications (ZM) is on analysts’ radars
• TAT Technologies (NASDAQ: TATT) is an under-the-radar pick gaining traction with smart money
• Why Eli Lilly (NYSE: LLY) is gaining momentum — and why it could last

P.S. Did you miss last week's picks? Get them here.

1- TAT Technologies (NASDAQ: TATT)

TAT Technologies is an aerospace company, that, like many of its peers and rivals, doubles as a defense contractor. However, it stands out by being a provider of highly specialized products — thermal management and environmental control systems. Despite not enjoying widespread coverage, TATT has recently attracted the attention of one of Wall Street’s premier analysts.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $27.70 — get current quote > 

Max 1-year forecast: $35.00 

Why we’re watching:

• This is an interesting case — only one analyst currently covers TATT stock, and he has given it a Strong Buy rating. See the rating
• That one analyst is Benchmark’s Josh Sullivan (a top 1% rated analyst), who doubled down on a Strong Buy rating on April 3 and increased his price target from $30 to $35.
• The revised price target was issued after TAT Technologies reported its Q4 and FY 2025 earnings.   
• Sullivan said the results beat Benchmark's revenue and margin estimates in the company's "ninth consecutive quarter of growth.
• Looking ahead, the analyst predicted "this streak will continue," citing expanded capabilities in APU repairs, an emerging landing gear cycle, increased leasing/trading contributions, and strong heat exchanger demand.
• Our rating system seems to agree with Sullivan’s bullish outlook. TAT Technologies stock has an overall Zen Rating of A, and ranks in the 95th percentile of stocks when taking into account 115 proprietary factors that correlate with outsized returns.
• Momentum is TAT Technologies’ strongest Component Grade rating — beyond those 9 consecutive earnings beats, it has seen stock prices increase by 141.71% in the last 365 days. In terms of this rating, it ranks in the top 4% of stocks
• However, TAT shares also rank highly in terms of Sentiment and Artificial Intelligence — in both cases, in the top 11%. (See all 7 Zen Component Grades here >)

2- Zoom Communications (NASDAQ: ZM)

Let’s jump on a quick call, and we’ll explain why Zoom deserves a closer look. Just kidding — while you might think of Zoom as yesterday’s news in comparison to, say, Microsoft Teams, Google Meet, or Slack (and it probably brings up not-so-pleasant memories of a global pandemic), the business has made ample strides in growing enterprise revenue and reducing customer churn.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $72.41   — get current quote > 

Max 1-year forecast: $115.00 

Why we’re watching:

• At present, 19 analysts issue ratings for Zoom stock. While a majority — 12, to be exact, have given it a Hold rating, the stock also has 4 Buy ratings, 3 Strong Buy ratings, and not a single Sell or Strong Sell rating. See the ratings
• Despite the numerous hold ratings, analysts are still projecting plenty of upside — the average price forecast for ZM shares, at $90.74, would equate to a 27.19% rally from current prices.
• Rosenblatt researcher Catharine Trebnick (a top 10% rated analyst) recently doubled down on a Strong Buy rating, maintaining a $95 price target.   
• Trebnick credited better scalability, comprehensive sales enablement tools, and strategic regionalization as key growth drivers going forward.
• Our proprietary quant rating system has given ZM shares the highest possible Zen Rating — an A. In fact, Zoom stock currently ranks in the 96th percentile of all equities.
• There’s plenty to like here in terms of Component Grade ratings, but two factors that are all the more important in times of economic uncertainty — Value and Financials, stand apart from the rest. In terms of the former, Zoom ranks in the top 8% of stocks — in terms of the latter, it ranks in the top 4%. (See all 7 Zen Component Grades here >)

3- Eli Lilly & Co (NYSE: LLY)

Weight loss drugs put pharma stocks back in the spotlight — Mounjaro and tirzepatide did it for Eli Lilly. In 2024, the business marked a 32% increase in full-year revenue — exceeding its own guidance by a staggering $4 billion. Those weight loss drugs have only one major flaw — at this point, they’re all injectable. However, Eli Lilly is set to release phase 3 trial data for Orforglipron — an oral weight-loss drug, later this year, in what could prove to be a major bullish catalyst.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $732.41 — get current quote > 

Max 1-year forecast: $1,190.00

Why we’re watching:

• There’s a strong bullish consensus regarding Eli Lilly on the Street — out of a total of 10 ratings, 9 are Strong Buys, rounded out by a single Buy rating. No Hold, Sell, or Strong Sell ratings are currently issued. See the ratings
• IN addition, the average 12-month price target for LLY shares, which stands at $1,042.70, implies a hefty 42.37% upside.
• On April 9, Morgan Stanley researcher Terence Flynn (a top 8% rated analyst), maintained a Strong Buy rating on Eli Lilly stock, but cut his price target from $1,146 to $1,124. 
• Flynn said a deep dive into their Healthcare (Pharma & Biotech) portfolio catalyzed their price target cut on Eli Lilly & Co.
• In preparation for the group's Q1 2025 earnings, the analyst said they updated their large-cap pharmaceutical and biotech models to account for IQVIA trends and intra-quarter data.
• At present, LLY is the 4th highest-rated stock in the General Drug Manufacturing industry.
• Eli Lilly stock carries an overall Zen Rating of A, and currently ranks in the top 5% of the more than 4,600 stocks tracked by our rating system.  
• Growth is currently Eli Lilly’s strongest Component Grade rating — a high degree of projected earnings growth, as well as the fact that margins have expanded from 15.4% to 23.5% over the last year, has earned LLY shares a spot in the top 7% of equities in this category. (See all 7 Zen Component Grades here >)

4- Carnival Corp (NYSE: CCL)

Carnival Corp has staged an impressive post-pandemic recovery, with occupancy rates nearing historic levels. The cruise giant has also made headway on deleveraging its balance sheet, trimming billions in debt while improving margins. Yet despite the rebound, CCL remains well below its pre-COVID highs — and while macro worries remain, long-term investors are presented with a discounted entry into a resurging industry leader. 

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $17.64 — get current quote > 

Max 1-year forecast: $33.00

Why we’re watching:

• Carnival Corp’s recovery hasn’t gone unnoticed. The stock has 7 Strong Buy ratings, 1 Buy rating, and 4 Hold ratings — no Sells or Strong Sells here. See the ratings
• The average 12-month price forecast for CCL shares sits at $28.83 — which implies a 63.45% upside.
• Tigress Financial researcher Ivan Feinseth (a top 4% rated analyst) increased his price target from $28 to $32 and maintained a Strong Buy rating following the company’s Q1 2025 earnings call.
• Feinseth cited strong booking volumes and ongoing strength in cruise demand as the key drivers behind his decision.
• At present, CCL shares have a Zen Rating of B. On average, this class of equities has outperformed the wider market for the past two and a half decades.
• Carnival Corp stock ranks quite highly in terms of Value — in the top 4%, to be exact. However, its Sentiment Component Grade rating is even more impressive — in that category, it ranks in the top 1% of stocks. (See all 7 Zen Component Grades here >)

5- Nutex Health (NASDAQ: NUTX)

We’re kicking this week off with something a little different compared to our standard fare. Nutex Health stock has surged by 84.99% in a week, 187.96% in a month, and 329.23% in the past three months. At present, it has just two analysts covering it. However, this isn’t a late April Fool's joke — there’s obviously something at play here, and we believe it deserves attention.

Zen Rating: A (Strong Buy)  — see full analysis >  

Recent Price: $132.03 — get current quote > 

Max 1-year forecast: $150.00 

Why we’re watching:

• Since we used the intro to give you a slightly bigger-picture view, let’s backtrack here. Nutex Health operates small-scale health facilities, micro-hospitals, and speciality hospitals, as well as a cloud-based platform that aggregates clinical and claims data.
• Under the No Surpises Act, the company has started to submit as much as 70% of its billable visits to arbitration — allowing it to counteract insurer underpayment. Their success rate under arbitration currently stands at roughly 80%.
• For the company’s latest quarterly report, analysts were expecting to see a $0.12 loss per share — instead, Nutex posted a gain of $11.12 per share. In addition, revenues more than tripled on a year-over-year (YoY) basis.
• Benchmark’s Bill Sutherland (a top 26% rated analyst) maintained a Strong Buy rating on Nutex Health stock, and increased his price target from $45 to $60 in the aftermath. Now, he has once again increased his price target — this time to $150. 
• Sutherland called the quarter "another big beat from top to bottom," highlighted by revenue and Adjusted EBITDA growth of 26% and 974%, respectively.
• The analyst explained that Nutex Health's "initiatives to increase patient volumes for higher-value services continued to drive growth and margin expansion."
• NUTX has a Zen Rating of A. Stocks of this caliber have provided an average annual return of 32.52% since the turn of the millennium. At present, Nutex Health stock ranks in the top 2% of equities per our proprietary quant rating system.
• Nutex Health is also the top-rated stock in the Health Information Service industry.
• In terms of Component Grade ratings, NUTX shares rank highly in terms of Sentiment, Growth, and Momentum — in the top 2%, 3%, and 5%, respectively. (See all 7 Zen Component Grades here >)
• P.S. — this is a highly unusual one, so we’d recommend quite a bit of caution. There’s no telling whether or not the arbitration strategy is sustainable. With that being said, it was put into place in July of 2024 — but even though it seems to be working at the moment, there’s plenty of policy risk here.

BONUS: STRONG SELL: Intel Corp (NASDAQ: INTC)

This time around, we’ll also close out this week’s picks with something different. As the great Kenny Rogers once said, you’ve got to know when to hold ‘em, know when to fold 'em — and in the case of Intel, you should definitely fold. While a recent deal and leadership changes have opened the door for positive developments down the line, the metrics simply haven’t improved yet. If you hold Intel stock, especially if you’re in the green on the trade, we’d recommend selling.

Zen Rating: F (Strong Sell) — see full analysis >  

Recent Price: $19.74   — get current quote > 

Max 1-year forecast: $29.00  

Why we’re watching:

• At present, 15 analysts issue ratings for Intel stock. It remains a consensus Hold, with 1 Buy rating, 11 Hold ratings, and 3 Strong Sell ratings. See the ratings
• JP Morgan’s Harlan Sur (a top 3% rated analyst) recently doubled down on a Strong Sell rating, and cut his price target for INTC stock from $26 to $23.  
• Overall, the analyst told readers that, in Intel, JP Morgan sees a company "continuing to navigate through a challenging period as it right-sizes at the same as attempting to move forward with its technology/manufacturing product roadmaps."
• At present, Intel stock has the lowest-possible rating per our system — an F. Stocks with this rating have provided an average annual loss of 8.02% since the turn of the century. Moreover, in the 2022 bear market, F-rated stocks lost an average of 58.05% in value.
• On the whole, INTC ranks in the bottom 3% of the equities we track. 
• Not a single Component Grade rating of Intel’s is a B or A. On the opposite side of the spectrum, it has three Component Grade ratings that are Fs — ranking in the bottom 15% in terms of Financials, and the bottom 18% in terms of Momentum and Growth (See all 7 Zen Component Grades here >)

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.